Metal-based antitumor compounds: beyond cisplatin
Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatm...
Gespeichert in:
| Veröffentlicht in: | Future medicinal chemistry 2019-01, Vol.11 (2), p.119-135 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 135 |
|---|---|
| container_issue | 2 |
| container_start_page | 119 |
| container_title | Future medicinal chemistry |
| container_volume | 11 |
| creator | Simpson, Peter V Desai, Nima Maheshkumar Casari, Ilaria Massi, Massimiliano Falasca, Marco |
| description | Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells. |
| doi_str_mv | 10.4155/fmc-2018-0248 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179357002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2216551006</sourcerecordid><originalsourceid>FETCH-LOGICAL-c371t-571079e083518b4f9b81416352c38b8f7207b4d4d3896637b4d18a47d0fc1b213</originalsourceid><addsrcrecordid>eNp1kLtLBDEQh4Mo3qFX2sqBjU00k8cmayeHLzix0Tpks1nIsS-T3eL-e7PseYXgNDMD3_wYPoSugNxxEOK-aiymBBQmlKsTtAQpMqxyKk-PM-QLtIpxR1IxqvJMnKMFIxnnjMolgnc3mBoXJrpybdrBD2PThbXtmr4b2zI-rAu379pybX3sazP49hKdVaaObnXoF-jr-elz84q3Hy9vm8cttkzCgIUEInNHFBOgCl7lhQIOGRPUMlWoSlIiC17ykqWfMjbNoAyXJaksFBTYBbqdc_vQfY8uDrrx0bq6Nq3rxqgpyJwJSQhN6M0fdNeNoU3faUohEwIIyRKFZ8qGLsbgKt0H35iw10D0pFMnnXrSqSedib8-pI5F48oj_SsvAfkMVOMwBhetd611et7Shbe-df-E_wDRsoCK</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2216551006</pqid></control><display><type>article</type><title>Metal-based antitumor compounds: beyond cisplatin</title><source>MEDLINE</source><source>PubMed Central</source><creator>Simpson, Peter V ; Desai, Nima Maheshkumar ; Casari, Ilaria ; Massi, Massimiliano ; Falasca, Marco</creator><creatorcontrib>Simpson, Peter V ; Desai, Nima Maheshkumar ; Casari, Ilaria ; Massi, Massimiliano ; Falasca, Marco</creatorcontrib><description>Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.</description><identifier>ISSN: 1756-8919</identifier><identifier>EISSN: 1756-8927</identifier><identifier>DOI: 10.4155/fmc-2018-0248</identifier><identifier>PMID: 30644327</identifier><language>eng</language><publisher>England: Future Science Ltd</publisher><subject>Animals ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - pharmacology ; Antineoplastic Agents - therapeutic use ; Antineoplastic drugs ; Antitumor agents ; Apoptosis ; Brain tumors ; Cancer ; Cancer therapies ; Carboplatin - chemistry ; Carboplatin - pharmacology ; Carboplatin - therapeutic use ; Cell cycle ; Chemoresistance ; Chemotherapy ; Cisplatin ; Cisplatin - chemistry ; Cisplatin - pharmacology ; Cisplatin - therapeutic use ; Copper - chemistry ; Copper - pharmacology ; Copper - therapeutic use ; Cytotoxicity ; Disease ; Drug Discovery ; Drugs ; Gold - chemistry ; Gold - pharmacology ; Gold - therapeutic use ; Hodgkin's lymphoma ; Humans ; Iridium - chemistry ; Iridium - pharmacology ; Iridium - therapeutic use ; Iron - chemistry ; Iron - pharmacology ; Iron - therapeutic use ; Kinases ; Leukemia ; Lymphoma ; Medical research ; metal-based anticancer agents ; Metals - chemistry ; Metals - pharmacology ; Metals - therapeutic use ; Neoplasms - drug therapy ; Nitrogen ; Organometallic Compounds - chemistry ; Organometallic Compounds - pharmacology ; Organometallic Compounds - therapeutic use ; Ovarian cancer ; Pancreas ; Pancreatic cancer ; Prostate ; Rhenium - chemistry ; Rhenium - pharmacology ; Rhenium - therapeutic use ; Rhodium - chemistry ; Rhodium - pharmacology ; Rhodium - therapeutic use ; Ruthenium - chemistry ; Ruthenium - pharmacology ; Ruthenium - therapeutic use ; Success ; Testicular cancer ; Tumors ; Vitamin B</subject><ispartof>Future medicinal chemistry, 2019-01, Vol.11 (2), p.119-135</ispartof><rights>2019 Newlands Press</rights><rights>Copyright Newlands Press Jan 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c371t-571079e083518b4f9b81416352c38b8f7207b4d4d3896637b4d18a47d0fc1b213</citedby><cites>FETCH-LOGICAL-c371t-571079e083518b4f9b81416352c38b8f7207b4d4d3896637b4d18a47d0fc1b213</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27907,27908</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30644327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Simpson, Peter V</creatorcontrib><creatorcontrib>Desai, Nima Maheshkumar</creatorcontrib><creatorcontrib>Casari, Ilaria</creatorcontrib><creatorcontrib>Massi, Massimiliano</creatorcontrib><creatorcontrib>Falasca, Marco</creatorcontrib><title>Metal-based antitumor compounds: beyond cisplatin</title><title>Future medicinal chemistry</title><addtitle>Future Med Chem</addtitle><description>Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.</description><subject>Animals</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Antineoplastic drugs</subject><subject>Antitumor agents</subject><subject>Apoptosis</subject><subject>Brain tumors</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carboplatin - chemistry</subject><subject>Carboplatin - pharmacology</subject><subject>Carboplatin - therapeutic use</subject><subject>Cell cycle</subject><subject>Chemoresistance</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Cisplatin - chemistry</subject><subject>Cisplatin - pharmacology</subject><subject>Cisplatin - therapeutic use</subject><subject>Copper - chemistry</subject><subject>Copper - pharmacology</subject><subject>Copper - therapeutic use</subject><subject>Cytotoxicity</subject><subject>Disease</subject><subject>Drug Discovery</subject><subject>Drugs</subject><subject>Gold - chemistry</subject><subject>Gold - pharmacology</subject><subject>Gold - therapeutic use</subject><subject>Hodgkin's lymphoma</subject><subject>Humans</subject><subject>Iridium - chemistry</subject><subject>Iridium - pharmacology</subject><subject>Iridium - therapeutic use</subject><subject>Iron - chemistry</subject><subject>Iron - pharmacology</subject><subject>Iron - therapeutic use</subject><subject>Kinases</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Medical research</subject><subject>metal-based anticancer agents</subject><subject>Metals - chemistry</subject><subject>Metals - pharmacology</subject><subject>Metals - therapeutic use</subject><subject>Neoplasms - drug therapy</subject><subject>Nitrogen</subject><subject>Organometallic Compounds - chemistry</subject><subject>Organometallic Compounds - pharmacology</subject><subject>Organometallic Compounds - therapeutic use</subject><subject>Ovarian cancer</subject><subject>Pancreas</subject><subject>Pancreatic cancer</subject><subject>Prostate</subject><subject>Rhenium - chemistry</subject><subject>Rhenium - pharmacology</subject><subject>Rhenium - therapeutic use</subject><subject>Rhodium - chemistry</subject><subject>Rhodium - pharmacology</subject><subject>Rhodium - therapeutic use</subject><subject>Ruthenium - chemistry</subject><subject>Ruthenium - pharmacology</subject><subject>Ruthenium - therapeutic use</subject><subject>Success</subject><subject>Testicular cancer</subject><subject>Tumors</subject><subject>Vitamin B</subject><issn>1756-8919</issn><issn>1756-8927</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kLtLBDEQh4Mo3qFX2sqBjU00k8cmayeHLzix0Tpks1nIsS-T3eL-e7PseYXgNDMD3_wYPoSugNxxEOK-aiymBBQmlKsTtAQpMqxyKk-PM-QLtIpxR1IxqvJMnKMFIxnnjMolgnc3mBoXJrpybdrBD2PThbXtmr4b2zI-rAu379pybX3sazP49hKdVaaObnXoF-jr-elz84q3Hy9vm8cttkzCgIUEInNHFBOgCl7lhQIOGRPUMlWoSlIiC17ykqWfMjbNoAyXJaksFBTYBbqdc_vQfY8uDrrx0bq6Nq3rxqgpyJwJSQhN6M0fdNeNoU3faUohEwIIyRKFZ8qGLsbgKt0H35iw10D0pFMnnXrSqSedib8-pI5F48oj_SsvAfkMVOMwBhetd611et7Shbe-df-E_wDRsoCK</recordid><startdate>20190101</startdate><startdate>20190101</startdate><enddate>20190101</enddate><enddate>20190101</enddate><creator>Simpson, Peter V</creator><creator>Desai, Nima Maheshkumar</creator><creator>Casari, Ilaria</creator><creator>Massi, Massimiliano</creator><creator>Falasca, Marco</creator><general>Future Science Ltd</general><general>Newlands Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M7P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20190101</creationdate><title>Metal-based antitumor compounds: beyond cisplatin</title><author>Simpson, Peter V ; Desai, Nima Maheshkumar ; Casari, Ilaria ; Massi, Massimiliano ; Falasca, Marco</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c371t-571079e083518b4f9b81416352c38b8f7207b4d4d3896637b4d18a47d0fc1b213</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Animals</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Antineoplastic drugs</topic><topic>Antitumor agents</topic><topic>Apoptosis</topic><topic>Brain tumors</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carboplatin - chemistry</topic><topic>Carboplatin - pharmacology</topic><topic>Carboplatin - therapeutic use</topic><topic>Cell cycle</topic><topic>Chemoresistance</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Cisplatin - chemistry</topic><topic>Cisplatin - pharmacology</topic><topic>Cisplatin - therapeutic use</topic><topic>Copper - chemistry</topic><topic>Copper - pharmacology</topic><topic>Copper - therapeutic use</topic><topic>Cytotoxicity</topic><topic>Disease</topic><topic>Drug Discovery</topic><topic>Drugs</topic><topic>Gold - chemistry</topic><topic>Gold - pharmacology</topic><topic>Gold - therapeutic use</topic><topic>Hodgkin's lymphoma</topic><topic>Humans</topic><topic>Iridium - chemistry</topic><topic>Iridium - pharmacology</topic><topic>Iridium - therapeutic use</topic><topic>Iron - chemistry</topic><topic>Iron - pharmacology</topic><topic>Iron - therapeutic use</topic><topic>Kinases</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Medical research</topic><topic>metal-based anticancer agents</topic><topic>Metals - chemistry</topic><topic>Metals - pharmacology</topic><topic>Metals - therapeutic use</topic><topic>Neoplasms - drug therapy</topic><topic>Nitrogen</topic><topic>Organometallic Compounds - chemistry</topic><topic>Organometallic Compounds - pharmacology</topic><topic>Organometallic Compounds - therapeutic use</topic><topic>Ovarian cancer</topic><topic>Pancreas</topic><topic>Pancreatic cancer</topic><topic>Prostate</topic><topic>Rhenium - chemistry</topic><topic>Rhenium - pharmacology</topic><topic>Rhenium - therapeutic use</topic><topic>Rhodium - chemistry</topic><topic>Rhodium - pharmacology</topic><topic>Rhodium - therapeutic use</topic><topic>Ruthenium - chemistry</topic><topic>Ruthenium - pharmacology</topic><topic>Ruthenium - therapeutic use</topic><topic>Success</topic><topic>Testicular cancer</topic><topic>Tumors</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Simpson, Peter V</creatorcontrib><creatorcontrib>Desai, Nima Maheshkumar</creatorcontrib><creatorcontrib>Casari, Ilaria</creatorcontrib><creatorcontrib>Massi, Massimiliano</creatorcontrib><creatorcontrib>Falasca, Marco</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Biological Science Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Future medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Simpson, Peter V</au><au>Desai, Nima Maheshkumar</au><au>Casari, Ilaria</au><au>Massi, Massimiliano</au><au>Falasca, Marco</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Metal-based antitumor compounds: beyond cisplatin</atitle><jtitle>Future medicinal chemistry</jtitle><addtitle>Future Med Chem</addtitle><date>2019-01-01</date><date>2019-01-01</date><risdate>2019</risdate><risdate>2019</risdate><volume>11</volume><issue>2</issue><spage>119</spage><epage>135</epage><pages>119-135</pages><issn>1756-8919</issn><eissn>1756-8927</eissn><abstract>Despite improvements in the 5-year survival rate to over 80% in cancers, such as Hodgkin lymphoma and testicular cancer, more aggressive tumors including pancreatic and brain cancer still have extremely low survival rates. The establishment of chemoresistance, responsible for the reduction in treatment efficiency and cancer relapse, is one possible explanation for this setback. Metal-based compounds, a class of anticancer drugs, are largely used in the treatment of cancer. Herein, we will review the use of metal-based small molecules in chemotherapy, focusing on recent studies, and we will discuss how new nonplatinum-based agents are prompting scientists to increase drug specificity to overcome chemoresistance in cancer cells.</abstract><cop>England</cop><pub>Future Science Ltd</pub><pmid>30644327</pmid><doi>10.4155/fmc-2018-0248</doi><tpages>17</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1756-8919 |
| ispartof | Future medicinal chemistry, 2019-01, Vol.11 (2), p.119-135 |
| issn | 1756-8919 1756-8927 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179357002 |
| source | MEDLINE; PubMed Central |
| subjects | Animals Antineoplastic Agents - chemistry Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Antineoplastic drugs Antitumor agents Apoptosis Brain tumors Cancer Cancer therapies Carboplatin - chemistry Carboplatin - pharmacology Carboplatin - therapeutic use Cell cycle Chemoresistance Chemotherapy Cisplatin Cisplatin - chemistry Cisplatin - pharmacology Cisplatin - therapeutic use Copper - chemistry Copper - pharmacology Copper - therapeutic use Cytotoxicity Disease Drug Discovery Drugs Gold - chemistry Gold - pharmacology Gold - therapeutic use Hodgkin's lymphoma Humans Iridium - chemistry Iridium - pharmacology Iridium - therapeutic use Iron - chemistry Iron - pharmacology Iron - therapeutic use Kinases Leukemia Lymphoma Medical research metal-based anticancer agents Metals - chemistry Metals - pharmacology Metals - therapeutic use Neoplasms - drug therapy Nitrogen Organometallic Compounds - chemistry Organometallic Compounds - pharmacology Organometallic Compounds - therapeutic use Ovarian cancer Pancreas Pancreatic cancer Prostate Rhenium - chemistry Rhenium - pharmacology Rhenium - therapeutic use Rhodium - chemistry Rhodium - pharmacology Rhodium - therapeutic use Ruthenium - chemistry Ruthenium - pharmacology Ruthenium - therapeutic use Success Testicular cancer Tumors Vitamin B |
| title | Metal-based antitumor compounds: beyond cisplatin |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T16%3A22%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Metal-based%20antitumor%20compounds:%20beyond%20cisplatin&rft.jtitle=Future%20medicinal%20chemistry&rft.au=Simpson,%20Peter%20V&rft.date=2019-01-01&rft.volume=11&rft.issue=2&rft.spage=119&rft.epage=135&rft.pages=119-135&rft.issn=1756-8919&rft.eissn=1756-8927&rft_id=info:doi/10.4155/fmc-2018-0248&rft_dat=%3Cproquest_cross%3E2216551006%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2216551006&rft_id=info:pmid/30644327&rfr_iscdi=true |